GoAI
Get started
Haemonetics Corporation logo

Haemonetics Corporation

HAE

NYSEHealthcareMedical - Devices

Open in GoAI

Previous close

$108.8

+$0.58 · +0.54%

Aug 21, 4:00 PM ET

HAE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

76

Undervalued

Momentum

52

Neutral

Sentiment

61

Bullish

Risk resilience

70

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Christopher A. Simon
Listed since
May 10, 1991
Employees
3,009

Market position

Day range

Current $108.8

52-week range

Current $108.8

Open
$108.32
Previous close
$108.22
Volume
443.49K
0.51× average
Average volume
872.78K
Average daily volume
Market cap
4.94B USD
Beta
0.52
Market reference 1
50-day average
$81.8534
+32.92% above average
200-day average
$70.8301
+53.61% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.53B USD
P/E (TTM)
52.82×
P/B (TTM)
5.9×
P/S (TTM)
3.66×
EV / EBITDA
11.29×
Earnings yield
3.82%
Free cash flow yield
10.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
57.38%
Operating margin
18.18%
Net margin
7.12%
Return on equity
12.22%
Return on assets
4.06%
Return on invested capital
8.66%

Financial health

Debt / equity
1.4×
Current ratio
2.95×
Altman Z-score
3.19
Piotroski F-score
8 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends62%41%20%-1%Gross margin, FY2022: 53.44%Gross margin, FY2023: 53.30%Gross margin, FY2024: 54.38%Gross margin, FY2025: 57.21%Gross margin, FY2026: 55.74%Operating margin, FY2022: 8.13%Operating margin, FY2023: 13.35%Operating margin, FY2024: 12.60%Operating margin, FY2025: 16.30%Operating margin, FY2026: 18.10%Net margin, FY2022: 4.37%Net margin, FY2023: 9.87%Net margin, FY2024: 8.98%Net margin, FY2025: 12.32%Net margin, FY2026: 7.29%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 53.44%. Gross margin FY2023 53.30%. Gross margin FY2024 54.38%. Gross margin FY2025 57.21%. Gross margin FY2026 55.74%. Operating margin FY2022 8.13%. Operating margin FY2023 13.35%. Operating margin FY2024 12.60%. Operating margin FY2025 16.30%. Operating margin FY2026 18.10%. Net margin FY2022 4.37%. Net margin FY2023 9.87%. Net margin FY2024 8.98%. Net margin FY2025 12.32%. Net margin FY2026 7.29%.

Income trends

Revenue

1.33B USD-1.97%

Operating income

241.4M USD+8.83%

Net income

97.31M USD-41.97%
Income trends across reported periods1.49B USD965.59M USD438.61M USD−88.37M USDRevenue, FY2022: 993.2M USDRevenue, FY2023: 1.17B USDRevenue, FY2024: 1.31B USDRevenue, FY2025: 1.36B USDRevenue, FY2026: 1.33B USDOperating income, FY2022: 80.75M USDOperating income, FY2023: 156.03M USDOperating income, FY2024: 164.88M USDOperating income, FY2025: 221.82M USDOperating income, FY2026: 241.4M USDNet income, FY2022: 43.38M USDNet income, FY2023: 115.4M USDNet income, FY2024: 117.56M USDNet income, FY2025: 167.68M USDNet income, FY2026: 97.31M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 993.2M USD. Revenue FY2023 1.17B USD. Revenue FY2024 1.31B USD. Revenue FY2025 1.36B USD. Revenue FY2026 1.33B USD. Operating income FY2022 80.75M USD. Operating income FY2023 156.03M USD. Operating income FY2024 164.88M USD. Operating income FY2025 221.82M USD. Operating income FY2026 241.4M USD. Net income FY2022 43.38M USD. Net income FY2023 115.4M USD. Net income FY2024 117.56M USD. Net income FY2025 167.68M USD. Net income FY2026 97.31M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue1.33B USD1.36B USD1.31B USD1.17B USD993.2M USD
Cost of goods sold590.44M USD582.28M USD597.14M USD545.79M USD462.43M USD
Gross profit743.59M USD778.55M USD711.92M USD622.87M USD530.77M USD
Research and development59.77M USD69.42M USD63.04M USD58.63M USD55.2M USD
Selling, general, and administrative442.42M USD422.05M USD420.82M USD373.95M USD332.2M USD
Operating expenses502.19M USD556.73M USD547.03M USD466.84M USD450.02M USD
Interest expense28.7M USD9.75M USD13.02M USD14.63M USD17.12M USD
Depreciation and amortization155.72M USD108.89M USD88.62M USD84.81M USD86.55M USD
Operating income241.4M USD221.82M USD164.88M USD156.03M USD80.75M USD
Net income97.31M USD167.68M USD117.56M USD115.4M USD43.38M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+4.14%
11 comparable reports
Latest EPS result
1.14
Estimate 1.08 · Beat by 5.56%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.361.231.090.96Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 1.19, estimate 1.18, surprise +0.85%, Beat. Q2 2025, reported May 8, 2025: actual 1.24, estimate 1.22, surprise +1.64%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.1, estimate 1.01, surprise +8.91%, Beat. Q4 2025, reported Nov 6, 2025: actual 1.27, estimate 1.12, surprise +13.39%, Beat. Q1 2026, reported Feb 5, 2026: actual 1.31, estimate 1.27, surprise +3.15%, Beat. Q2 2026, reported May 7, 2026: actual 1.29, estimate 1.28, surprise +0.78%, Beat. Q3 2026, reported Aug 6, 2026: actual 1.14, estimate 1.08, surprise +5.56%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.31, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates368.64M345.19M321.74M298.29MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 348.54M USD, estimate 354.46M USD, surprise -1.67%, Miss. Q2 2025, reported May 8, 2025: actual 330.6M USD, estimate 312.47M USD, surprise +5.80%, Beat. Q3 2025, reported Aug 7, 2025: actual 321.39M USD, estimate 320.01M USD, surprise +0.43%, Beat. Q4 2025, reported Nov 6, 2025: actual 327.32M USD, estimate 329.77M USD, surprise -0.75%, Miss. Q1 2026, reported Feb 5, 2026: actual 339M USD, estimate 331.92M USD, surprise +2.13%, Beat. Q2 2026, reported May 7, 2026: actual 346.35M USD, estimate 336.83M USD, surprise +2.83%, Beat. Q3 2026, reported Aug 6, 2026: actual 339.38M USD, estimate 327.86M USD, surprise +3.51%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 345.03M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$104.6

3.86% downside
Past 12 months12-month forecastHigh $119Average $104.6Low $85.00

Rating distribution

21 ratings
Strong buy00%
Buy1152%
Hold1048%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions
B of A SecuritiesupgradeNeutralBuy

HAE news

seekingalpha.com

Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model

Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular…

Read source
defenseworld.net

Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE

Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE: HAE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm…

Read source
gurufocus.com

Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors

On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with

Read source
zacks.com

Here's Why Haemonetics (HAE) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read source
zacks.com

Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read source
zacks.com

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

Read source

Corporate actions

Corporate action history

Stock split

Effective Dec 3, 2012

2:1

Stock split

Effective Jan 11, 1993

2:1

HAE peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding HAE

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
145.1M
Weight
0.11%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
130.72M
Weight
0.16%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
123.79M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
89.38M
Weight
0.05%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
45.79M
Weight
0.05%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
44.69M
Weight
0.30%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
State Street SPDR S&P MIDCAP 400 ETF Trust logoState Street SPDR S&P MIDCAP 400 ETF TrustMDY
Market value
36.83M
Weight
0.14%
AUM
26.72B USD
Expense ratio
0.23%
Price / 1D
$699.6+0.48%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
28.38M
Weight
0.04%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%

Continue in GoAI

Research HAE

research.disclaimer